We are live on ! Find out more
NEXI

NexImmune, Inc. Common Stock

Delisted

NEXI was delisted on the 11th of July, 2024.

46 hedge funds and large institutions have $47.1M invested in NexImmune, Inc. Common Stock in 2021 Q4 according to their latest regulatory filings, with 8 funds opening new positions, 12 increasing their positions, 11 reducing their positions, and 9 closing their positions.

New
Increased
Maintained
Reduced
Closed

9% more repeat investments, than reductions

Existing positions increased: 12 | Existing positions reduced: 11

2% less funds holding

Funds holding: 4746 (-1)

11% less first-time investments, than exits

New positions opened: 8 | Existing positions closed: 9

71% less capital invested

Capital invested by funds: $160M → $47.1M (-$113M)

Holders
46
Holders Change
-1
Holders Change %
-2.13%
% of All Funds
0.71%
Holding in Top 10
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
8
Increased
12
Reduced
11
Closed
9
Calls
Puts
Net Calls
Net Calls Change
Name Holding Trade Value Shares
Change
Change in
Stake
MIM
51
MetLife Investment Management
New Jersey
-$117K -308 Closed
SG Americas Securities
52
SG Americas Securities
New York
-$114K -301 Closed
MLICM
53
Metropolitan Life Insurance Company (MetLife)
New York
-$88.2K -233 Closed
US Bancorp
54
US Bancorp
Minnesota
-$2K -5 Closed

NEXI Hedge Fund Activity: Q4 2021 in Review

46 of the 6,499 institutional investors tracked by Wall St. Rank reported a position in NexImmune, Inc. Common Stock (NEXI) for Q4 2021, worth a combined $47.1M — down 71% from $160M a quarter earlier.

Sellers outnumbered buyers: 9 funds closed out of NEXI and 8 opened new positions — a net loss of 1 holder — while 11 trimmed existing stakes and 12 added.

The largest buyer was JP Morgan Private Wealth Advisors, opening a new position worth an estimated $961K. The largest seller was Suvretta Capital Management, exiting entirely with an estimated $5.21M sold.

  • 46 institutional investors held NexImmune, Inc. Common Stock (NEXI) as of Q4 2021, down from 47 in Q3 2021.
  • Funds reported $47.1M of NexImmune, Inc. Common Stock stock for Q4 2021, down 71% quarter-over-quarter.
  • 8 funds opened new NexImmune, Inc. Common Stock positions in Q4 2021 and 9 closed out, a net change of -1 holder.
  • The largest NexImmune, Inc. Common Stock buyer in Q4 2021 was JP Morgan Private Wealth Advisors, an estimated $961K added.
  • The largest NexImmune, Inc. Common Stock seller in Q4 2021 was Suvretta Capital Management, an estimated $5.21M sold.

Based on aggregated 13F filings for Q4 2021.